Efficacy of the first generation EGFR-TKI plus apatinib in the treatment of advanced lung adenocarcinoma after drug resistance

doi:10.3969/j.issn.1672-3384.2020.12.007

FENG Yu, ZHU Hao-hua, HU Xing-sheng, LIU Yu-tao, XING Pu-yuan, WANG Hong-yu, JI Xue, DAI Zhong, SHI Yuan-kai

Clinical Medication Journal ›› 2020, Vol. 18 ›› Issue (12) : 32-38.

PDF(1179 KB)

Clinical Medication Journal ›› 2020, Vol. 18 ›› Issue (12) : 32-38. DOI: 10.3969/j.issn.1672-3384.2020.12.007

Original Articles

Efficacy of the first generation EGFR-TKI plus apatinib in the treatment of advanced lung adenocarcinoma after drug resistance

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2020, 18(12): 32-38 https://doi.org/10.3969/j.issn.1672-3384.2020.12.007

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(1179 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2020-02-06	2020-12-01
Issue Date
2020-12-01

Please choose a citation manager

Content to export